- Home
- AGFY vs INKT Comparison
AGFY vs INKT Comparison
Compare AGFY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGFY
- INKT
- Stock Information
- Founded
- AGFY 2016
- INKT 2017
- Country
- AGFY United States
- INKT United States
- Employees
- AGFY N/A
- INKT N/A
- Industry
- AGFY Military/Government/Technical
- INKT Medicinal Chemicals and Botanical Products
- Sector
- AGFY Consumer Discretionary
- INKT Health Care
- Exchange
- AGFY Nasdaq
- INKT Nasdaq
- Market Cap
- AGFY 41.3M
- INKT 48.7M
- IPO Year
- AGFY 2021
- INKT 2021
- Fundamental
- Price
- AGFY $30.48
- INKT $14.91
- Analyst Decision
- AGFY
- INKT Buy
- Analyst Count
- AGFY 0
- INKT 3
- Target Price
- AGFY N/A
- INKT $37.50
- AVG Volume (30 Days)
- AGFY 13.3K
- INKT 201.7K
- Earning Date
- AGFY 08-08-2025
- INKT 08-14-2025
- Dividend Yield
- AGFY N/A
- INKT N/A
- EPS Growth
- AGFY N/A
- INKT N/A
- EPS
- AGFY N/A
- INKT N/A
- Revenue
- AGFY $12,260,000.00
- INKT N/A
- Revenue This Year
- AGFY N/A
- INKT N/A
- Revenue Next Year
- AGFY N/A
- INKT N/A
- P/E Ratio
- AGFY N/A
- INKT N/A
- Revenue Growth
- AGFY 186.99
- INKT N/A
- 52 Week Low
- AGFY $2.71
- INKT $4.56
- 52 Week High
- AGFY $84.44
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- AGFY 67.36
- INKT 49.04
- Support Level
- AGFY $28.93
- INKT $13.10
- Resistance Level
- AGFY $35.63
- INKT $18.00
- Average True Range (ATR)
- AGFY 2.21
- INKT 2.10
- MACD
- AGFY 0.61
- INKT -0.26
- Stochastic Oscillator
- AGFY 55.83
- INKT 44.28
About AGFY Agrify Corporation
Agrify Corp is a developer of branded inventive solutions for the cannabis and hemp industries. Its Senorita brand offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror cocktails like a margarita - in three flavors - classic Lime Jalapeno Margarita, Mango Margarita, and Paloma. In addition to beverages, Agrify has also historically been a provider of inventive cultivation and extraction solutions for the cannabis industry. Its comprehensive extraction product line, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.